Lexicon gets FDA approval for Inpefa to treat heart failure

Lexicon Pharmaceuticals (Lexicon) has received approval from the US Food and Drug Administration (FDA) for its Inpefa drug to treat heart failure.

Inpefa is a once-daily oral tablet indicated as an inhibitor of sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1).

It is intended to lower the risk of cardiovascular death, urgent heart failure visit, and hospitalisation for heart failure.